1. Medtech Insight
  2. >>Archive

Cyberonics' VNS device approved for epilepsy in Japan

 
• By Madeleine Armstrong

The vagus nerve stimulation (VNS) therapy system developed by Cyberonics (Houston, Texas) has been approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of drug-resistant epilepsy. The device, which is already approved in the US for both refractory epilepsy and depression, delivers electrical pulses to the vagus nerve via a generator that is implanted in the chest. This stimulation is designed to prevent the electrical irregularities in the brain that cause seizures. Tokyo-based Nihon Kohden is the exclusive distributor of the device in Japan.

The vagus nerve stimulation (VNS) therapy system developed by Cyberonics (Houston, Texas) has been approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of drug-resistant epilepsy. The device, which is already approved in the US for both refractory epilepsy and depression, delivers electrical pulses to the vagus nerve via a generator that is implanted in the chest. This stimulation is designed to prevent the electrical irregularities in the brain that cause seizures. Tokyo-based Nihon Kohden is the exclusive distributor of the device in Japan.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

Fresh Off $100M IPO, Carlsmed Plans For Growth, 2026 Launch Of Customized Cervical Fusion Implant

 
• By Marion Webb

Fresh off an IPO, spinal implant maker Carlsmed is preparing to launch a new cervical fusion application for its aprevo tech. Medtech Insight has two perspectives on these recent moves: CEO Mike Cordonnier and the doctor who performed the first spinal fusion using the technology.

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 
• By Natasha Barrow

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.

BD Sees $90M Tariff Hit In Q4; 2026 Impact Reduced To $275M

 
• By Shubham Singh

BD raised its adjusted earnings per share guidance midpoint by $0.18 to a range of $14.30 to $14.45, representing growth of about 9.4% at the midpoint – an increase of approximately 1.4% over prior guidance.